HRO350 / Arctic Biosci - LARVOL DELTA

Beyond skin deep: Baseline systemic immune-inflammatory index as predictor of treatment response of HRO350 in mild-to-moderate psoriasis. Results from the HeROPA study (EADV-Sp 2026) - P2 | "Stratifying patients based on baseline SII enhanced treatment effect detection in a patient population prone to high placebo responses and whose disease severity assessments are limited by insufficiently granular clinical assessment tools. SII stratification provides an accessible tool for increasing treatment sensitivity and predicting responder trajectories in mild to moderate psoriasis."

Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis

Arctic Bioscience - 12-month data confirm potential for HRO350 in mild-to-moderate psoriasis (Cision) - P2b | N=521 | HeROPA (NCT06125808) | Sponsor: Arctic Bioscience | "12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05). Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported. While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of HRO350."

P2b data • Psoriasis

Arctic Bioscience – HeROPA 1-year read-out: Top-line results expected within 2-3 weeks (Cision) - "All patients have completed 1 year of treatment and the HeROPA phase 2b clinical trial on HRO350 in mild-to-moderate psoriasis is completed. Top-line results were planned to be announced by end of Q1 2025, however cleaning of the comprehensive dataset from more than 500 patients for 1 year of treatment is taking more time than anticipated. The top-line data are currently being cleaned and quality controlled. Top-line results are expected to be published within 2-3 weeks. Analyses on all endpoints will then be presented in the full clinical study report in May this year."

P2b data • Psoriasis

Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study). (clinicaltrials.gov) - P2 | N=521 | Completed | Sponsor: Arctic Bioscience | Active, not recruiting ➔ Completed | Trial primary completion date: Feb 2025 ➔ Oct 2024

Trial completion • Trial primary completion date • Dermatology • Immunology • Psoriasis

Efficacy and Safety Study of HRO350 in Patients With Mild-to-moderate Psoriasis (the 'HeROPA' Study). (clinicaltrials.gov) - P2 | N=521 | Active, not recruiting | Sponsor: Arctic Bioscience | Recruiting ➔ Active, not recruiting | Phase classification: P2b ➔ P2

Enrollment closed • Phase classification • Dermatology • Immunology • Psoriasis